Hypothalamic-pituitary-adrenal axis following glucocorticoid prophylaxis against acute mountain sickness.
The pituitary-adrenocortical and adrenomedullary response to high altitude (HA) stress was studied following daily single dose administration of prednisolone as a prophylaxis against altitude-induced acute mountain sickness (AMS). Forty healthy men, randomly divided into two groups of twenty, received placebo or prednisolone 20 mg once a day at 08.00 h for two days prior to induction to HA and during an initial three days stay at an altitude of 3450 m. The AMS score and circulatory levels of ACTH, cortisol, epinephrine and norepinephrine were measured at sea level (SL) and during residency at HA. The sensitivity of the hypothalamic-pituitary-adrenal axis in subjects receiving prednisolone therapy was evaluated at SL and on day four of stay at HA. Administration of prednisolone significantly (p < 0.01) decreased the severity of AMS in all the subjects. The steroid dose used did not inhibit endogenous secretion of ACTH, cortisol, epinephrine or norepinephrine, as HA response to adrenocortical and adrenomedullary hormones was identical in placebo and prednisolone treated subjects. The integrity of the hypothalamic-pituitary-adrenal axis was maintained well in subjects receiving low dose prednisolone therapy. These observations suggest that short-term administration of prednisolone is able to curtail AMS without causing suppression of the hypothalamic-pituitary-adrenal axis.
Basu
M
M
Defence Institute of Physiology and Allied Sciences, Timarpur, Delhi, India. em_dispas@yahoo.com
Sawhney
R C
RC
Kumar
S
S
Pal
K
K
Prasad
R
R
Selvamurthy
W
W
D000311:Adrenal Glands / Q000187:drug effects / Q000503:physiopathology*; D000324:Adrenocorticotropic Hormone / Q000097:blood; D000328:Adult; D000532:Altitude Sickness / Q000503:physiopathology / Q000517:prevention & control*; D001786:Blood Glucose / Q000032:analysis; D004837:Epinephrine / Q000097:blood; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007003:Hypoglycemia / Q000097:blood; D007031:Hypothalamus / Q000187:drug effects / Q000503:physiopathology*; D007328:Insulin; D007700:Kinetics; D008297:Male; D009638:Norepinephrine / Q000097:blood; D010902:Pituitary Gland / Q000187:drug effects / Q000503:physiopathology*; D010919:Placebos; D011239:Prednisolone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
D001786:Blood Glucose; D005938:Glucocorticoids; D007328:Insulin; D010919:Placebos; D000324:Adrenocorticotropic Hormone; D011239:Prednisolone; D006854:Hydrocortisone; D009638:Norepinephrine; D004837:Epinephrine